EBITDA for Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current EBITDA (TTM) is $472.68M USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$472.68M
YoY change
-411.6%
5Y CAGR
N/A
Peak year (2025)
$557.24M
Cumulative EBITDA
-$5.66B
EBITDA history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
EBITDA history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $557.24M | -411.6% | ||
| 2024 | -$178.85M | -30.7% | ||
| 2023 | -$258.24M | -72.1% | ||
| 2022 | -$926.56M | +40.1% | ||
| 2021 | -$661.56M | -10.2% | ||
| 2020 | -$736.33M | -15.2% | ||
| 2019 | -$868.08M | +15.1% | ||
| 2018 | -$754.24M | +54.5% | ||
| 2017 | -$488.19M | +19.2% | ||
| 2016 | -$409.46M | +47.8% | ||
| 2015 | -$276.96M | +60.8% | ||
| 2014 | -$172.29M | +108.3% | ||
| 2013 | -$82.71M | +59.9% | ||
| 2012 | -$51.71M | +4.1% | ||
| 2011 | -$49.69M | +30.6% | ||
| 2010 | -$38.06M | -7.2% | ||
| 2009 | -$41.02M | +116.6% | ||
| 2008 | -$18.93M | -74.8% | ||
| 2007 | -$75.06M | +110.3% | ||
| 2006 | -$35.69M | -8.1% | ||
| 2005 | -$38.83M | +31.4% | ||
| 2004 | -$29.55M | +50.7% | ||
| 2003 | -$19.61M | +368.5% | ||
| 2002 | -$4.19M | — |
EBITDA values are taken from Alnylam Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Alnylam Pharmaceuticals (ALNY) most recent annual EBITDA stands at $557.24M (2025) – plunged 411.6% year-over-year.
Across the available history, EBITDA reached its high of $557.24M in 2025 and its low of -$926.56M in 2022.
Among 8 Healthcare peers, Alnylam Pharmaceuticals (ALNY) ranks 9th; the peer median for EBITDA is $24.21B.
Alnylam Pharmaceuticals EBITDA by Year
Alnylam Pharmaceuticals EBITDA 2025: $557.24M
Alnylam Pharmaceuticals EBITDA in 2025 was $557.24M, plunged 411.6% below 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals EBITDA 2024: -$178.85M
Alnylam Pharmaceuticals EBITDA in 2024 was -$178.85M, plunged 30.7% below 2023.
Alnylam Pharmaceuticals EBITDA 2023: -$258.24M
Alnylam Pharmaceuticals EBITDA in 2023 was -$258.24M, plunged 72.1% below 2022.
Alnylam Pharmaceuticals EBITDA 2022: -$926.56M
Alnylam Pharmaceuticals EBITDA in 2022 was -$926.56M, surged 40.1% from 2021. This figure represents the lowest annual value in the available history.
Alnylam Pharmaceuticals EBITDA 2021: -$661.56M
Alnylam Pharmaceuticals EBITDA in 2021 was -$661.56M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — EBITDA
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's EBITDA?
- Latest reported EBITDA for Alnylam Pharmaceuticals (ALNY) is $472.68M (period ending December 31, 2025).
How has Alnylam Pharmaceuticals EBITDA changed year-over-year?
- Alnylam Pharmaceuticals (ALNY) EBITDA changed -411.6% year-over-year on the latest annual filing.
When did Alnylam Pharmaceuticals EBITDA hit its highest annual value?
- Alnylam Pharmaceuticals EBITDA reached its highest annual value of $557.24M in 2025.
What was Alnylam Pharmaceuticals EBITDA in 2024?
- Alnylam Pharmaceuticals (ALNY) EBITDA in 2024 was -$178.85M.
What was Alnylam Pharmaceuticals EBITDA in 2025?
- Alnylam Pharmaceuticals (ALNY) EBITDA in 2025 was $557.24M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.